European Medicines Agency initiatives and perspectives on pharmacogenomics

British Journal of Clinical Pharmacology

Volumn 77, Issue 4, 2014, Pages 612-617

  Ehmann, Falk ^a   Caneva, Laura ^a   Papaluca, Marisa ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

European Medicines Agency; guidance; pharmacoepigenetics; pharmacogenomics; regulator

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AFATINIB; AXITINIB; BOSUTINIB; BRENTUXIMAB VEDOTIN; CARBAMAZEPINE; CETUXIMAB; CRIZOTINIB; DABRAFENIB; DARIFENACIN; DASATINIB; DOCETAXEL; EVEROLIMUS; FESOTERODINE; GEFITINIB; HLA A ANTIGEN; HLA B ANTIGEN; IMATINIB; IVACAFTOR; LAPATINIB; PANITUMUMAB; PERTUZUMAB; PONATINIB; RANOLAZINE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VEMURAFENIB;

ARTICLE; COST BENEFIT ANALYSIS; DRUG INFORMATION; DRUG RESPONSE; DRUG SURVEILLANCE PROGRAM; GENETIC POLYMORPHISM; GENOTYPE; HEALTH CARE SYSTEM; HUMAN; MEDICAL SOCIETY; MEDICATION COMPLIANCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REIMBURSEMENT; DRUG DEVELOPMENT; EUROPE; PHARMACOGENETICS; PRACTICE GUIDELINE; TRENDS;

DRUG DISCOVERY; EUROPE; GUIDELINES AS TOPIC; HUMANS; PHARMACOGENETICS; PHARMACOVIGILANCE;

EID: 84897869777     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12319     Document Type: Article

References (25)

1. ICH E15: definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. Available at http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/ definitions-for-genomic-biomarkers-pharmacogenomics-pharmacogenetics-genomic- data-and-sample-cod.html (last accessed 7 December 2013).
2. European Commission guideline on summary of product characteristics (SmPC). Available at http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc- guideline-rev2-en.pdf (last accessed 7 December 2013).
3. EMA: guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/ 02/WC500121954.pdf (last accessed 7 December 2013).
4. Guideline on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products, Draft. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/ 01/WC500160232.pdf (last accessed 14 March 2014).
5. Maliepaard M, Nofziger C, Papaluca M, Zineh I, Uyama Y, Prasad K, Grimstein C, Pacanowski M, Ehmann F, Dossena S, Paulmichl M,. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov 2013; 12: 103-115. doi: 10.1038/nrd3931.
6. European Medicines Agency (EMA). European public assessment reports. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/ landing/epar-search.jsp&mid=WC0b01ac058001d124 (last accessed 7 December 2013).
7. EMA product information: Xaluprine, mercaptopurine. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002022/WC500124645.pdf (last accessed 7 December 2013).
8. EMA product information: clopidogrel Apotex, clopidogrel. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001189/WC500029701.pdf (last accessed 7 December 2013).
9. EMA product information: Ziagen, abacavir. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000252/WC500050343.pdf (last accessed 7 December 2013).
10. Innovation task force (ITF) at the European medicines agency (EMA). Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/ general/general-content-000334.jsp&mid=WC0b01ac05800ba1d9 (last accessed 7 December 2013).
11. Emerging science at the EMA. Available at http://www.ema.europa.eu/ema/ index.jsp?curl=pages/special-topics/general/general-content-000339.jsp&mid= WC0b01ac05800baed8 (last accessed 7 December 2013).
12. Ehmann F, Papaluca Amati M, Salmonson T, Posch M, Vamvakas S, Hemmings R, Eichler HG, Schneider CK,. Gatekeepers and enablers: how drug regulators Respond to a challenging and changing environment by moving toward a proactive attitude. Clin Pharmacol Ther 2013; 93: 425-432. doi: 10.1038/clpt.2013.14.
13. EMA scientific advice procedure. Available at http://www.ema.europa.eu/ ema/index.jsp?curl=pages/regulation/general/general-content-000049.jsp&mid= WC0b01ac05800229b9 (last accessed 7 December 2013).
14. EMA qualification of novel methodologies for medicine development. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/ document-listing/document-listing-000319.jsp&mid=WC0b01ac0580022bb0 (last accessed 7 December 2013).
15. Shah RR, Shah DR,. Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol 2012; 74: 698-721.
16. PhVWP monthly report on safety concerns, guidelines and general matters. July 2012-Issue number: 1207. Available at http://www.ema.europa.eu/docs/en-GB/ document-library/Report/2012/07/WC500130391.pdf (last accessed 7 December 2013).
17. Joint EMA scientific advice with HTA bodies. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners-and-networks/general/ general-content-000476.jsp&mid=WC0b01ac0580236a57 (last accessed 7 December 2013).
18. European Medicines Agency/health-technology-assessment-body workshop on parallel scientific advice in drug development. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/events/2013/ 06/event-detail-000721.jsp&mid=WC0b01ac058004d5c3 (last accessed 7 December 2013).
19. Simon R, Roychowdhury S,. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013; 12: 358-369. doi: 10.1038/nrd3979.
20. Fridlyand J, Simon RM, Walrath JC, Roach N, Buller R, Schenkein DP, Flaherty KT, Allen JD, Sigal EV, Scher HI,. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov 2013; 12: 743-755. doi: 10.1038/nrd4101.
21. European public assessment report (EPAR) for herceptin (trastuzumab). Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/000278/human-med-000818.jsp&mid=WC0b01ac058001d124 (last accessed 7 December 2013).
22. Workshop on pharmacogenomics: from science to clinical care; Report of the workshop held on 8-9 October 2012 at the European Medicines Agency. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Report/2012/ 11/WC500134968.pdf (last accessed 7 December 2013).
23. Patel JN, McLeod HL, Innocenti F,. Implications of genome-wide association studies in cancer therapeutics. Br J Clin Pharmacol 2013; 76: 370-380.
24. Amstutz U, Carleton BC,. Pharmacogenetic testing: time for clinical practice guidelines. Clin Pharmacol Ther 2011; 89: 924-927. doi: 10.1038/clpt.2011.18.
25. European Commission DG Justice. European Commission justice data protection legislation. Available at http://ec.europa.eu/justice/data- protection/law/index-en.htm (last accessed 7 December 2013).